Longevity
Thymalin
aka thymalin · thymus polypeptide complex · calf thymus extract · thymulin (NB: different peptide — often confused) · khavinson thymic bioregulator
Grade
A Soviet-era extract of calf thymus glands, claimed to "reset" an ageing immune system — backed by decades of striking-looking Russian longevity data that almost nobody outside Russia has been able to check or repeat.
- Class
- Polypeptide complex (mixture of short peptides) extracted from calf thymus
- Evidence
- Grade C · Early / limited human data
- Sport / WADA
- Not specifically named on the WADA Prohibited List. As an immune-modulating tissue extract it is not a classic doping agent (not a hormone, anabolic or growth-factor secretagogue), so it is not generally a focus for anti-doping. Athletes should still treat any undefined unlicensed extract with caution and check the current list, since contamination and adulteration of grey-market products are real risks.
- Last reviewed
- 2026-06
Grade C · Early / limited human data
Why this grade
There is genuine human data — including one small randomised single-blind controlled trial — which lifts it above animal/in-vitro-only (D). But it sits at the bottom of C: essentially the entire evidence base traces to one Russian research lineage (Khavinson and colleagues), the older studies predate modern RCT standards, and there is no independent or Western replication. Limited, single-lineage human evidence, not the robust trials that would justify B.
What is it?
Your thymus is a little gland behind your breastbone that trains your immune cells. It shrinks as you get older, which is part of why older people catch more bugs. Thymalin is made by mashing up the thymus glands of young calves and purifying a mixture of tiny protein fragments out of them. Russian scientists have injected it into older people for decades and reported that it perks the immune system back up — and in some long-running studies, that the people who got it lived noticeably longer. The catch is that almost all of this research comes from one Russian team, and the way the studies were run wouldn't pass the strict tests we'd expect today. So it's a genuinely interesting idea with a real story behind it, but not something that's been properly proven.
Think of it as a faded set of beautiful before-and-after photos from a single clinic, decades old, that no other clinic has ever managed to reproduce. The transformation looks remarkable — but until someone independent can take the same photos under proper lighting, you can't tell how much is real and how much is the camera angle.
How is it meant to work?
Thymalin is thought to work as an immune 'bioregulator' rather than a hormone replacement. The thymus normally educates T-lymphocytes; as it involutes with age, T-cell output and immune competence fall. Thymalin's purported active components are very short peptides (e.g. KE, EW, EDP) proposed to enter cells, bind DNA/histones and modulate gene expression, nudging stem cells and thymocytes toward T-cell differentiation and rebalancing cytokine signalling (Th1/Th2). In practice it is a crude tissue extract, so 'mechanism' here is partly inferred from its constituent peptides studied separately, not from a single well-characterised molecule.
What's it studied for?
Research contexts. Not proven uses, and not recommendations.
Does the human evidence stack up?
There is human data, which is unusual for a grey-market peptide — but it is heavily caveated. The bulk comes from Vladimir Khavinson's group in St Petersburg over several decades, including a frequently-cited 6–8 year programme in 266 elderly people reporting roughly a 2-fold drop in mortality with thymalin (and up to 4.1-fold combined with epithalamin). These were open-label, non-randomised, single-group studies that would not meet modern trial standards, and no independent Western team has reproduced them. The most methodologically credible study is Kuznik et al. (2021), a prospective randomised single-blind controlled trial of 80 older patients with severe COVID-19 (36 given added thymalin, 44 controls) where the thymalin arm had lower IL-6, lower CRP and roughly halved in-hospital mortality (19.4% vs 40.9%) — but it was single-centre, small, underpowered for mortality and not replicated, and came from the same research lineage. Net: a real but narrow, unverified human evidence base dominated by one research group.
What could go wrong?
- !Almost all efficacy data comes from a single research group over decades, with little independent or Western replication.
- !Older studies were largely non-blinded and non-randomised; effect sizes (e.g. multi-fold mortality reductions) are large enough to invite scepticism.
- !It is a crude animal-tissue extract of undefined composition, not a single defined molecule — batch-to-batch consistency and exactly what is being injected are unclear.
- !Biological-origin extracts carry theoretical contamination/immunogenicity concerns; grey-market 'research' material has no quality control.
- !Not a licensed medicine in the UK; anything sold here is an unlicensed product with no MHRA oversight.
- !Easily confused with thymulin (a different, zinc-dependent thymic nonapeptide) and with thymosin alpha-1.
Is it legal in the UK?
Thymalin is not a licensed medicine in the UK. It holds regulatory approval in Russia (and some former-Soviet states) for immune-deficiency indications, but the MHRA has not authorised it and neither has the EMA or FDA. In the UK it would be an unlicensed substance: selling it for human use would engage the Human Medicines Regulations 2012, so it circulates only as a grey-market 'research chemical' with no quality, safety or efficacy guarantees.
Key trials
- · Observational / open-label· Completed (2003)
6–8 year geroprotection programme in 266 elderly subjects (thymalin ± epithalamin)
Reported ~2-fold (thymalin) up to 4.1-fold (combined) mortality reduction. Non-randomised, non-blinded, single group — hypothesis-generating at best.
- · Randomised controlled trial (single-blind)· Completed (2021)
Thymalin in severe COVID-19 in older patients (Kuznik et al.)
80 patients (36 thymalin / 44 control); lower inflammation markers and in-hospital mortality 19.4% vs 40.9%. Single-centre, underpowered for mortality, unreplicated.
Sources
- 01Peptides of pineal gland and thymus prolong human life — Khavinson VKh, Morozov VG, Neuro Endocrinol Lett (2003)
The flagship 6–8 year geroprotection programme in 266 elderly subjects reporting multi-fold mortality reductions. Open-label, non-randomised — striking but methodologically weak. PMID verified.
- 02Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients — Kuznik BI, Khavinson VKh, Shapovalov KG, et al., Advances in Gerontology (2021)
Prospective randomised single-blind controlled trial, 80 older severe-COVID patients (36 thymalin / 44 control); lower IL-6/CRP and in-hospital mortality 19.4% vs 40.9%. Single-centre (Chita), underpowered for mortality, unreplicated — the most rigorous study available. DOI and PMC verified; a previously-cited PMID for this paper was wrong (pointed to an unrelated article) and has been removed.
- 03The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity (review) — Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM, PubMed Central (review) (2021)
Group's own review of mechanism and immunocorrection claims (KE/EW/EDP peptides) — useful for the proposed mechanism, but not independent evidence of efficacy. Verified.
- 04Thymalin: clinical and mechanistic studies (PubMed search) — Various, PubMed search (2024)
Entry point to the broader literature, the bulk of which traces to the Khavinson lineage.
Related
Stay posted
Follow Thymalin
We'll email you only when Thymalin's evidence actually changes — a new human trial, a grade change, a safety signal. No spam, nothing for sale.